The gene therapy developer, backed by Roche Venture Fund, floated in the middle of its range after raising more than $80m in venture funding.
AveXis, a US-based neurological disease treatment developer that counts pharmaceutical firm Roche among its investors, raised $95m when it floated on Nasdaq yesterday.
The company issued 4.75 million shares priced at $20.00 each, in the middle of the $19 to $21 range it set last week.
AveXis is developing gene therapy treatments for rare and potentially fatal neurological genetic diseases. Its lead product candidate, AVXS-101, is currently in a phase 1 clinical trial for spinal muscular atrophy, a…
